Establishment of a New Zealand White Rabbit Model for Lethal Toxin (LT) Challenge and Efficacy of Monoclonal Antibody 5E11 in the LT-Challenged Rabbit Model
Open Access
Abstract
Anthrax caused by Bacillus anthracis is a lethal infectious disease, especially when inhaled, and the mortality rate approaches 100% without treatment. The anthrax antitoxin monoclonal antibody (MAb) 5E11 is a humanized antibody that targets the anthrax protective antigen (PA). The efficacy of 5E11 needs proper animal models. However, anthrax spores are extremely dangerous, so experiments must be conducted under Biosafety Level 3 conditions. Considering the critical effects of lethal toxin (LT) on hosts during infection, we report the establishment of a LT-challenged rabbit model, which caused 100% mortality with a dose of 2 mg PA + 1 mg LF, while a 4 mg PA + 2 mg LF challenge could limit death to within three days. Then, we evaluated 5E11 efficacy against LT. A prophylactic study showed that the i.v. administration of 40 mg/kg 5E11 four days before lethal dose LT challenge could lead to 100% survival. In therapeutic studies, the i.v. administration of 40 mg/kg 5E11 10 min after lethal dose LT challenge could provide complete protection. Overall, we developed a new LT-challenged rabbit model, and our results indicate that 5E11 shows potential for the clinical application in anthrax treatment.Keywords
Funding Information
- National Natural Science Foundation of China (81172980)
- State Project for Essential Drug Research and Development (2016ZX09J16101)
This publication has 32 references indexed in Scilit:
- Evaluation of Intravenous Anthrax Immune Globulin for Treatment of Inhalation AnthraxAntimicrobial Agents and Chemotherapy, 2013
- Evaluation of Immunogenicity and Efficacy of Anthrax Vaccine Adsorbed for Postexposure ProphylaxisClinical and Vaccine Immunology, 2013
- Bacillus anthracis Protective Antigen Kinetics in Inhalation Spore-Challenged Untreated or Levofloxacin/ Raxibacumab-Treated New Zealand White RabbitsToxins, 2013
- Characterization of a Therapeutic Model of Inhalational Anthrax Using an Increase in Body Temperature in New Zealand White Rabbits as a Trigger for TreatmentClinical and Vaccine Immunology, 2012
- An overview of anthrax infection including the recently identified form of disease in injection drug usersIntensive Care Medicine, 2012
- Anthrax Lethal Toxin Disrupts Intestinal Barrier Function and Causes Systemic Infections with Enteric BacteriaPLOS ONE, 2012
- Antibiotics Cure Anthrax in Animal ModelsAntimicrobial Agents and Chemotherapy, 2011
- MyD88-Dependent Signaling Protects against Anthrax Lethal Toxin-Induced Impairment of Intestinal Barrier FunctionInfection and Immunity, 2011
- Cellular and systemic effects of anthrax lethal toxin and edema toxinMolecular Aspects of Medicine, 2009
- Selection of Bacillus anthracis isolates resistant to antibioticsJournal of Antimicrobial Chemotherapy, 2004